

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-52. (Cancelled)

53. (Currently Amended) A method of identifying a substance that interacts with a polypeptide-regulates JTT-1 antigen function, the method comprising:

providing a purified polypeptide comprising (a) an extracellular region of the polypeptide set forth in SEQ ID NO:2, or (b) an extracellular region of a polypeptide that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added, wherein the polypeptide comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) and inhibits the activation of lymphocytes-the extracellular domain of a JTT-1 antigen;

contacting the polypeptide with a test substance; and

determining whether the test substance interacts with the polypeptide, ~~wherein such interaction indicates that the test substance is a potential regulator of JTT-1 antigen.~~

54. (Previously Presented) The method of claim 53, wherein the polypeptide is a fusion protein.

55. (Previously Presented) The method of claim 54, wherein the fusion protein comprises a portion of a constant region of an immunoglobulin heavy chain.

56. (Currently Amended) The method of claim 53, wherein the polypeptide comprises ~~extracellular region~~ is amino acid residues 1-140 of SEQ ID NO:2.

57. (Previously Presented) The method of claim 53, wherein the test substance is a low molecular weight compound.

58. (Previously Presented) The method of claim 53, wherein the test substance is a polypeptide.

59. (Previously Presented) The method of claim 53, wherein the test substance is an antibody.

60-63. (Cancelled)

64. (Currently Amended) The method of claim 53, wherein the polypeptide human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2.

65. (Currently Amended) The method of claim 64, wherein the polypeptide human JTT-1 antigen consists of the amino acid sequence of SEQ ID NO:2.

66. (Previously Presented) The method of claim 65, wherein the test substance is a low molecular weight compound.

67. (Cancelled)

68. (Currently Amended) The method of claim 53, wherein the polypeptide human JTT-1 antigen comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein

(a) the polypeptide human JTT-1 antigen comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,

(b) the polypeptide human JTT-1 antigen comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and

(c) an antibody reactive with the polypeptide human JTT-1 antigen induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.

69. (Previously Presented) The method of claim 68, wherein the test substance is a low molecular weight compound.